News

China: NMPA Approves New Therapies | 2026

Badari Andukuri

16 hours ago

Italy | AIFA | Healthcare Updates | iPharmaCenter

Badari Andukuri

3 days ago

ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026

Badari Andukuri

5 days ago

Italy’s Medicine Spending Reaches €39.3 Billion in 2025 | iPharmaCenter

Badari Andukuri

5 days ago

NICE Backs Acalabrutinib for Mantle Cell Lymphoma and Untreated CLL

Badari Andukuri

7 days ago

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Badari Andukuri

Aug 5

FDA clears Pluvicto earlier in PSMA positive metastatic prostate cancer

Badari Andukuri

Aug 4

Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

Badari Andukuri

Aug 4

EU Approves Datroway as 1L Monotherapy in PD‑1/PD‑L1–Ineligible Metastatic TNBC After TROPION‑Breast02 Survival Gain

Badari Andukuri

Aug 3

UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy

Badari Andukuri

Jul 31

UnitedHealth Scales Tennessee Health Hubs with $4M to Reach 200,000 Residents by 2027

Badari Andukuri

Jul 31

European Commission Authorizes RINVOQ for Severe Alopecia Areata

Badari Andukuri

Jul 30

AstraZeneca's trastuzumab deruxtecan approved by CDSCO for adults with HER2-positive Stage II or III early breast cancer | iPharmaCenter

Badari Andukuri

Jul 30

Johnson & Johnson Expands Oncology and Immunology Pipelines via Multi-Billion-Dollar Deals | iPharmaCenter

Badari Andukuri

Jul 30

FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD

Badari Andukuri

Jul 27

Sanofi Terminates Amlitelimab Development in Atopic Dermatitis | iPharmaCenter

Badari Andukuri

Jul 26

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

Badari Andukuri

Jul 23

FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer

Badari Andukuri

Jul 22

India's CDSCO Grants Regulatory Approval for Takeda’s Qdenga Dengue Vaccine

Badari Andukuri

Jul 21

CMS Outlines Operational Path for 2028 Maximum Fair Price Compliance

Badari Andukuri

Jul 20

China: NMPA Approves New Therapies | 2026

Italy | AIFA | Healthcare Updates | iPharmaCenter

ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026

Italy’s Medicine Spending Reaches €39.3 Billion in 2025 | iPharmaCenter

NICE Backs Acalabrutinib for Mantle Cell Lymphoma and Untreated CLL

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

FDA clears Pluvicto earlier in PSMA positive metastatic prostate cancer

Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

EU Approves Datroway as 1L Monotherapy in PD‑1/PD‑L1–Ineligible Metastatic TNBC After TROPION‑Breast02 Survival Gain

UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy

UnitedHealth Scales Tennessee Health Hubs with $4M to Reach 200,000 Residents by 2027

European Commission Authorizes RINVOQ for Severe Alopecia Areata

AstraZeneca's trastuzumab deruxtecan approved by CDSCO for adults with HER2-positive Stage II or III early breast cancer | iPharmaCenter

Johnson & Johnson Expands Oncology and Immunology Pipelines via Multi-Billion-Dollar Deals | iPharmaCenter

FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD

Sanofi Terminates Amlitelimab Development in Atopic Dermatitis | iPharmaCenter

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer

India's CDSCO Grants Regulatory Approval for Takeda’s Qdenga Dengue Vaccine

CMS Outlines Operational Path for 2028 Maximum Fair Price Compliance

Join our mailing list